Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

CTI Technologies Inc.

Division of CTI BioPharma Corp.
www.cticseattle.com

Latest From CTI Technologies Inc.

With Remicade Biosimilar On The Rise, J&J Adds Astellas’ JAK2 To Pipeline

The unknowns of JAK inhibitors still offer substantial promise, and Pfizer will likely be the first test subject in the RA space.

BioPharmaceutical Japan

With Remicade Biosimilar On The Rise, J&J Adds Astellas’ JAK2 To Pipeline

The unknowns of JAK inhibitors still offer substantial promise, and Pfizer will likely be the first test subject in the RA space.

BioPharmaceutical Japan

Deal Statistics Quarterly, Q2 2005

In this issue, we present another installment of our quarterly review of dealmaking-for April-June 2005. Our data comes from Windhover's Strategic Intelligence Systems, which covers deal activity within the pharmaceutical/biotechnology, medical device, and in vitro diagnostics industries.

BioPharmaceutical Medical Device
See All

Company Information

  • Industry
  • Biotechnology
  • Pharmaceuticals
  • Therapeutic Areas
  • Non-Specific
  • Alias(es)
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • CTI BioPharma Corp.
  • Senior Management
  • Contact Info
  • CTI Technologies Inc.
    Phone: (206) 272-4000
    501 Elliott Avenue West
    Ste. 400
    Seattle, WA 98119
    USA
UsernamePublicRestriction

Register